Clearmind Medicine announces USD 7.5 Million Public Offering and uplisting to Nasdaq
Clearmind Medicine announced the price of its USD 7.5 Million Public Offering and uplisting to Nasdaq.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND”, the Frankfurt Stock Exchange under the symbol “CWY0” and on the OTC Markets under the symbol “CMNDF”.
The Company’s intellectual portfolio currently consists of seven patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind Medicine is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems.
The transaction was the work of Greenberg Traurig lawyers David Huberman and Gary Emanuel.
